No clinically relevant pharmacokinetic a
β
Rebecca Spence; Arun Mandagere; Brooke Harrison; Christopher Dufton; Ramesh Boin
π
Article
π
2009
π
John Wiley and Sons
π
English
β 225 KB
Ambrisentan is a nonsulfonamide, ET(A)-selective endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), and tadalafil is a phosphodiesterase type 5 (PDE-5) inhibitor under investigation for treatment of PAH. Due to the potential combination use, the